2017-03-07 20:45:27 UTC

AGA Institute GastroSlides Unit on Non-Alcoholic Fatty Liver Disease (NAFLD)



“Non-Alcoholic Fatty Liver Disease” is separated into the following sections: Part I: Introduction, Epidemiology and Definitions; Part II: Pathophysiology: Part III: Diagnosis and Treatment; Part IV: Illustrative Cases.


This teaching unit represents a set of images that illustrate the epidemiology, physiology, diagnosis and treatment of a rapidly emerging health concern: nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH). The outstanding photographs, micrographs, illustrations and animations explain important concepts in our understanding of the metabolic factors that lead to fat deposition and liver dysfunction. These images provide a scientific basis for the treatment of NAFLD and the prevention of complications, including cirrhosis, portal hypertension and liver cancer. Images, including graphic representations of data from key studies, are accompanied by explanatory legends that contain recent literature citations, thereby providing a unique teaching and self-educational resource. The senior author, Anna Mae Diehl, MD, is a professor of medicine and the chief of the Division of Gastroenterology, Duke University School of Medicine, Durham, NC.

About the Instructors


Anna Mae Diehl, MD, is a professor of medicine at Duke University School of Medicine, Durham, NC. Dr. Diehl did her GI and hepatology clinical fellowship at Johns Hopkins School of Medicine. She joined the faculty at Johns Hopkins in 1990 and moved to Duke University in 2004. Dr. Diehl is widely recognized in the field of hepatology and has a particular research interest in nonalcoholic fatty liver disease. She has served on the national advisory council for the National Institute on Alcohol Abuse and Alcoholism, national and international grant review panels, and scientific advisory boards for the National Institutes of Health (NIH). She is a recipient of the Leon Schiff Prize for outstanding research in clinical liver disease from the American Association for the Study of Liver Diseases and the Hans Popper Prize for outstanding basic liver research from the International Association for the Study of Liver Diseases. Dr. Diehl’s research is supported by NIH. 


Jerry Schoendorf, MAMS
Chapel Hill, NC

Stan Coffman
Durham, NC


The author thanks Dr. James B. McGee, University of Pittsburgh School of Medicine, for providing the template for clinical cases and for his helpful comments, and Dr. Jean-Pierre Raufman, University of Maryland School of Medicine, for providing some of the micrographs and for reviewing and editing the unit.

Published Date and Terms of Use

The content included in this GastroSlide set, Non-Alcoholic Fatty Liver Disease (NAFLD), was published on May 15, 2005. This slide set has not been updated since the date of publication and is provided “as is.” It is the learner's responsibility to evaluate the accuracy of any information found within these educational materials.

The intent of this series is to provide individual clinicians and educators with materials to use in their educational activities, such as lecturing at continuing medical education meetings and for self-education. AGA encourages all uses of GastroSlide materials consistent with this objective.

Materials are to be displayed in the same content and form as the original with no alterations unless approved by AGA. No materials may be reproduced for any purpose without written permission of AGA. Materials may only be used for educational purposes and may not be used to promote or advertise any pharmaceutical, medical device or organization.

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.


More on Non-Alcoholic Fatty Liver Disease (NAFLD)

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Blog: Restricting Fructose to Reduce Fatty Liver Disease

Sept. 19, 2017

Researchers report that reducing dietary fructose decreases liver fat in children with obesity and metabolic syndrome. Read more in the AGA Journals blog.

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

Sept. 1, 2017

PDFF estimated by MRI scanners of different field strength and at different sites, accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a reference.